Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: A downhole activation system within a tubular. The system includes an axially movable member; a first magnetic field source having a first field with a first axial orientation movable with the member. A second magnetic field source having a second field with an axial orientation different from the first orientation and separated from the first magnetic field source. The second field being magnetically repulsed by the first field; and, a biasing device urging the second magnetic field source towards the first magnetic field source; wherein movement of the first magnet via the member towards the second magnet moves the second magnet in a direction against the biasing device. A method of activating an activatable member in a downhole tubular.

Abstract: A downhole activation system within a tubular. The system includes an axially movable mover. A first magnet attached to the mover. The first magnet axially movable with the mover. A second magnet separated from the first magnet. The second magnet magnetically repulsed by the first magnet. A biasing device urging the second magnet towards the first magnet; wherein movement of the first magnet via the mover towards the second magnet moves the second magnet in a direction against the biasing device. Also included is a method of activating an activatable member in a downhole tubular.

Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: Systems and methods for building road models, driver models, and vehicle models and making predictions may use driving data received from a plurality of vehicles being driving along a path by a driver. The driving data including a minimum of vehicle location preferably supplemented by data related to the time of observations, vehicle dynamics, and various vehicle sensors. The received data may be categorized into a plurality of maneuvers and a plurality of variables that describe the maneuvers and the received driving data may be identified. A road model may then be built for the path based on the identified variables and maneuvers and the behaviors of a particular driver compared to the road model to assess their driving and intervene as appropriate.

Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: Systems and methods for building road models, driver models, and vehicle models and making predictions may use driving data received from a plurality of vehicles being driving along a path by a driver. The driving data including a minimum of vehicle location preferably supplemented by data related to the time of observations, vehicle dynamics, and various vehicle sensors. The received data may be categorized into a plurality of maneuvers and a plurality of variables that describe the maneuvers and the received driving data may be identified. A road model may then be built for the path based on the identified variables and maneuvers and the behaviors of a particular driver compared to the road model to assess their driving and intervene as appropriate.

Abstract: Systems and methods for building road models, driver models, and vehicle models and making predictions may use driving data received from a plurality of vehicles being driving along a path by a driver. The driving data including a minimum of vehicle location preferably supplemented by data related to the time of observations, vehicle dynamics, and various vehicle sensors. The received data may be categorized into a plurality of maneuvers and a plurality of variables that describe the maneuvers and the received driving data may be identified. A road model may then be built for the path based on the identified variables and maneuvers and the behaviors of a particular driver compared to the road model to assess their driving and intervene as appropriate.

Abstract: A transmission line structure having a pair of separated coplanar waveguide transmissions line section. A coupling circuit is coupled between the pair of coplanar waveguide transmissions line sections, the coupling circuit suppresses common mode signals therein and passes, substantially unsuppressed, differential mode signal transmission between the pair of coplanar waveguide transmissions line sections.

Abstract: A sediment retention device including a water-permeable outer containment structure, a water-impermeable injection tube including an outlet disposed within the outer containment structure, and a flocculent treatment material disposed within the injection tube. The injection tube can include an agitation structure to promote mixing contaminated water with the treatment material. A baffle including water distribution openings can be disposed over the outlet to distribute water into the outer containment structure.

Abstract: In some embodiments, a wastewater treatment system may reduce contaminants in water. A system may include one or more bioreactors which include a substrate that supports a biofilm The bacteria used to form the biofilm may be selected to maximize the reduction of contaminants in water. Various components of the wastewater treatment system may be optimized to improve the efficiency and energy consumption of the wastewater system.

Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: A downhole activation system within a tubular. The system includes an axially movable member; a first magnetic field source having a first field with a first axial orientation movable with the member. A second magnetic field source having a second field with an axial orientation different from the first orientation and separated from the first magnetic field source. The second field being magnetically repulsed by the first field; and, a biasing device urging the second magnetic field source towards the first magnetic field source; wherein movement of the first magnet via the member towards the second magnet moves the second magnet in a direction against the biasing device. A method of activating an activatable member in a downhole tubular.

Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: A wrapping apparatus for wrapping a sheet of a covering material from a roll onto an outer surface of a surgical site. The wrapping apparatus includes a handle and a body portion having a housing, a first end, and a second end. The housing and the first and second ends generally defining an interior region that is configured to receive the placement of the roll. The wrapping apparatus further includes first and second spindles that are configured to allow rotation of the roll relative to the handle for the dispensing of the sheet of covering material from the roll. The wrapping apparatus may also include a cap that is operably connected to the second end, and which secures the roll to the wrapping apparatus. Additionally, the wrapping apparatus may include a cutting apparatus that cuts or tears dispensed covering material away from the roll of covering material.

Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Abstract: A downhole activation system within a tubular. The system includes an axially movable mover. A first magnet attached to the mover. The first magnet axially movable with the mover. A second magnet separated from the first magnet. The second magnet magnetically repulsed by the first magnet. A biasing device urging the second magnet towards the first magnet; wherein movement of the first magnet via the mover towards the second magnet moves the second magnet in a direction against the biasing device. Also included is a method of activating an activatable member in a downhole tubular.